Bankers and consultants have long been urging the virtues of consolidation onto a financially strapped biotech industry. But few companies on either side of the Atlantic have been listening.
Tracking intra-European dealmaking by type of acquirer and target, Windhover's Strategic Transactions Database shows that overall dealmaking has declined, with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?